P03.22.A USE OF POSITRON EMISSION TOMOGRAPHY (PET) IN PATIENTS WITH BRAIN TUMOURS AMONG EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - BRAIN TUMOUR GROUP (EORTC-BTG) SITES

Abstract BACKGROUND Data on the use of positron emission tomography (PET) among neuro-oncology centers in Europe are scarce. MATERIAL AND METHODS From 06/2024 to 08/2024, a cross-sectional survey among European Organization for Research and Treatment in Cancer - Brain Tumor Group (EORTC-BTG) sites was performed to gain insights into the availability and use of PET across brain tumor centers in Europe. RESULTS In total, 312 sites were invited, and 103 replies from 20 countries were recorded. PET was available at 96/103 (93.2%) sites, and 74 of these reported PET use in patients with central nervous system neoplasms. Most frequently, PET was performed in glioma (69/74, 93.2%), followed by brain metastasis (58/74, 78.4%), meningioma (52/74, 70.3%), and CNS lymphoma (46/74, 62.2%). Amino acid PET was performed at 62/71 sites (87.3%, 3 not reported [n.r.]), and most frequently in glioma (58/59, 98.3%) and for differentiation of treatment-related changes from tumour progression (58/59, 98.3%). The prevailing amino acid tracer was [18F]FET (45/59, 76.3%), followed by [18F]FDOPA (22/59, 37.3%) and [11C]methionine (15/59, 25.4%). Dynamic acquisition protocols for amino acid PET were used by 35/59 (59.3%) sites. Somatostatin receptor (SSTR) PET was applied at 50/68 sites (73.5%, 6 n.r.) and mainly in meningioma (48/49, 98.0%) and for patient selection before radioligand therapy (41/49, 83.7%) as well as for target volume definition in radiotherapy (33/49, 67.3%). PET was reportedly covered by statutory health insurance at 46/59 (78.0%) centres for amino acid PET and 33/49 (67.3%) for SSTR PET. Reasons for not using PET in clinical routine included limited availability of tracers (14/29, 48.3%), high cost (11/29, 37.9%), and PET not perceived necessary (8/29, 27.6%). CONCLUSION PET is widely used within the EORTC BTG network, underscoring the feasibility of PET-based clinical trial endpoints which support the generation of evidence for further implementation in clinical routine. As our survey may be prone to selection and non-response bias, a comprehensive analysis of PET application patterns would be desirable.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-10-01
DOI
https://doi.org/10.1093/neuonc/noaf193.181
Primary Topic
Chemical Reactions and Isotopes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P03.22.A USE OF POSITRON EMISSION TOMOGRAPHY (PET) IN PATIENTS WITH BRAIN TUMOURS AMONG EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - BRAIN TUMOUR GROUP (EORTC-BTG) SITES

Marika Rasschaert, M Smits, Mattias Belting, Michael Weller et al.
Neuro-Oncology
Chemical Reactions and Isotopes
article

P03.22.A USE OF POSITRON EMISSION TOMOGRAPHY (PET) IN PATIENTS WITH BRAIN TUMOURS AMONG EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - BRAIN TUMOUR GROUP (EORTC-BTG) SITES

Marika Rasschaert, M Smits, Mattias Belting, Michael Weller, Julia Furtner, Petter Brandal, Nathalie L. Albert, Martinus P G Broen, Francesco Cicone, Norbert Galldiks, François Ducray, Antoni Verger, Giuseppe Minniti, Felix Sahm, Maximilian Niyazi, Felix Ehret, Émilie Le Rhun, Alessia Pellerino, Maximilian J. Mair, M Preusser, Asgeir Store Jakola, Nelleke Tolboom, Evangelia D. Razis, Philipp Lohmann, Jean‐François Daisne
article en

Abstract

Abstract BACKGROUND Data on the use of positron emission tomography (PET) among neuro-oncology centers in Europe are scarce. MATERIAL AND METHODS From 06/2024 to 08/2024, a cross-sectional survey among European Organization for Research and Treatment in Cancer - Brain Tumor Group (EORTC-BTG) sites was performed to gain insights into the availability and use of PET across brain tumor centers in Europe. RESULTS In total, 312 sites were invited, and 103 replies from 20 countries were recorded. PET was available at 96/103 (93.2%) sites, and 74 of these reported PET use in patients with central nervous system neoplasms. Most frequently, PET was performed in glioma (69/74, 93.2%), followed by brain metastasis (58/74, 78.4%), meningioma (52/74, 70.3%), and CNS lymphoma (46/74, 62.2%). Amino acid PET was performed at 62/71 sites (87.3%, 3 not reported [n.r.]), and most frequently in glioma (58/59, 98.3%) and for differentiation of treatment-related changes from tumour progression (58/59, 98.3%). The prevailing amino acid tracer was [18F]FET (45/59, 76.3%), followed by [18F]FDOPA (22/59, 37.3%) and [11C]methionine (15/59, 25.4%). Dynamic acquisition protocols for amino acid PET were used by 35/59 (59.3%) sites. Somatostatin receptor (SSTR) PET was applied at 50/68 sites (73.5%, 6 n.r.) and mainly in meningioma (48/49, 98.0%) and for patient selection before radioligand therapy (41/49, 83.7%) as well as for target volume definition in radiotherapy (33/49, 67.3%). PET was reportedly covered by statutory health insurance at 46/59 (78.0%) centres for amino acid PET and 33/49 (67.3%) for SSTR PET. Reasons for not using PET in clinical routine included limited availability of tracers (14/29, 48.3%), high cost (11/29, 37.9%), and PET not perceived necessary (8/29, 27.6%). CONCLUSION PET is widely used within the EORTC BTG network, underscoring the feasibility of PET-based clinical trial endpoints which support the generation of evidence for further implementation in clinical routine. As our survey may be prone to selection and non-response bias, a comprehensive analysis of PET application patterns would be desirable.

Neuro-OncologyVol. 27(Supplement_3)
Université Claude Bernard Lyon 1 (FR), Oslo University Hospital (NO), Danube Private University (AT), Forschungszentrum Jülich (DE), German Cancer Research Center (DE), University of Oslo (NO), Lund University (SE), University of Zurich (CH), Heidelberg University (DE), Maastricht University Medical Centre (NL), Sahlgrenska University Hospital (SE), Erasmus MC (NL), Istituto Neurologico Mediterraneo (IT), University Medical Center Utrecht (NL), LMU Klinikum (DE), Magna Graecia University (IT), Humboldt-Universität zu Berlin (DE), University Hospital of Zurich (CH), Antwerp University Hospital (BE), German Cancer Society (DE), Hôpital Pierre Wertheimer (FR), Neuroscience Institute (IT), Imagerie Adaptative Diagnostique et Interventionnelle (FR), Universitätsklinikum Aachen (DE), Hygeia Hospital (GR), Iridium Kankernetwerk (BE), Skåne University Hospital (SE), STZ eyetrial (DE), Erasmus MC Cancer Institute (NL), University Hospital Cologne (DE), Freie Universität Berlin (DE), Medical University of Vienna (AT), Charité - Universitätsmedizin Berlin (DE), University of Tübingen (DE), Ludwig-Maximilians-Universität München (DE), Sapienza University of Rome (IT), University of Gothenburg (SE), RWTH Aachen University (DE), Université de Lorraine (FR), Erasmus University Rotterdam (NL)
Openalex Percentile: Top 79%
Chemical Reactions and Isotopes
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.